Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 7/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | RARG | P13631 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117237 | 0.87 | KMT2A (0.59) | KMT2AMAPTALDH1A1KDM4EPKM | |
| SCHEMBL3117214 | 0.87 | KMT2A (0.59) | KMT2AMAPTALDH1A1KDM4EPKM | |
| SCHEMBL5381839 | 0.84 | PPARG (0.58) | KMT2AMAPTALDH1A1KDM4EPKM | |
| SCHEMBL4622907 | 0.84 | KMT2A (0.57) | KMT2AMAPTALDH1A1KDM4EPKM | |
| SCHEMBL7914462 | 0.84 | PPARG (0.58) | KMT2AMAPTALDH1A1KDM4EPKM | |
| SCHEMBL5374848 | 0.84 | PPARG (0.61) | KMT2AMAPTALDH1A1KDM4EPKM | |
| SCHEMBL1201631 | 0.83 | MAPT (0.66) | KMT2AMAPTALDH1A1KDM4EPKM | |
| SCHEMBL13674890 | 0.82 | KMT2A (0.58) | KMT2AMAPTALDH1A1KDM4EPKM | |
| SCHEMBL3127846 | 0.81 | KMT2A (0.57) | KMT2AMAPTALDH1A1KDM4EPKM | |
| SCHEMBL14018778 | 0.81 | KMT2A (0.57) | KMT2AMAPTALDH1A1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011098801-A1 | INFLAMMATORY DISEASE TREATMENT | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-08-18 | — | — | WO | disclosed |
| US-20090054493-A1 | THIAZOLE DERIVATIVES AS PPAR DELTA LIGANDS AND THEIR MANUFACTURING PROCESS | Kang, Heonjoong Kang (KR) | 2009-02-26 | — | — | US | disclosed |
| US-20090054493-A1 | THIAZOLE DERIVATIVES AS PPAR DELTA LIGANDS AND THEIR MANUFACTURING PROCESS | Kang, Heonjoong Kang (KR) | 2009-02-26 | — | — | US | disclosed |
| EP-1903042-A2 | An improved process for hydrogenation of 5-(substituted Benzylidene) 2,4- Thiazolidine Dione compounds to give corresponding ( +/- ) 5- (substituted Benzyl ) 2,4-Thiazolidine Dione | Cadila Pharmaceuticals Limited (IN) | 2008-03-26 | — | — | EP | disclosed |
| US-20070238757-A1 | NOVEL TREATMENT | SMITHKLINE BEECHAM P.L.C. | 2007-10-11 | — | — | US | disclosed |
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | disclosed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | disclosed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054493-A1 | THIAZOLE DERIVATIVES AS PPAR DELTA LIGANDS AND THEIR MANUFACTURING PROCESS | PPARD, PPARG, PPARA | KMT2A 4247/4885MAPT 3135/4885ALDH1A1 789/4885 |
| US-20070238757-A1 | NOVEL TREATMENT | PPARG, PPARA, NLN | KMT2A 3312/4885MAPT 330/4885ALDH1A1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.